Viewing data from:

NITAZOXANIDE

ANDA

NITAZOXANIDE | A213820 | RISING PHARMA HOLDINGS INC

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Nitazoxanide (2023)

Total Spending

$4.8M

Total Claims

3,358

Beneficiaries

2,613

Avg Cost/Unit

$90.27

Spending Trend

$120K(2020)→$5.1M(2021)→$5.4M(2022)→$4.8M(2023)

YoY Change:-13.0%

5yr CAGR:-8.4%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain9 active DMFs1 inactive

9 active API suppliers hold Drug Master Files for this ingredient.

ROMARK BELGIUM BVBANITAZOXANIDE

DMF 121241996

COHANCE LIFESCIENCES LTDNITAZOXANIDE

DMF 197522006

INDUSTRIALE CHIMICA SRLNITAZOXANIDE

DMF 237922010

DASAMI LAB PRIVATE LTDNITAZOXANIDE

DMF 330592019

MAPRIMED SANITAZOXANIDE

DMF 341502019

BIOPHORE INDIA PHARMACEUTICALS PVT LTDNITAZOXANIDE

DMF 341692019

MSN LIFE SCIENCES PRIVATE LTDNITAZOXANIDE

DMF 345552020

NIRA LIFE SCIENCES PVT LTDNITAZOXANIDE

DMF 384082023

SUN PHARMACEUTICAL INDUSTRIES LTDNITAZOXANIDE

DMF 389962023

CAMBREX PROFARMACO MILANO SRLInactiveNITAZOXANIDE

DMF 315412016

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Jan 12, 2021	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 500MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Nov 27, 2020

No patent or exclusivity listings for this strength.